Always view the negging of non-orthodox approaches to anything by the WSJ as anything but surprising. Furthermore, cui bono with respect to potential outcomes?

Always view the negging of non-orthodox approaches to anything by the WSJ as anything but surprising. Furthermore, cui bono with respect to potential outcomes? I think it's the pharma industry.